- The ODELIA research project aims to "overcome the obstacles of collecting information on the health of patients with guarantees" to advance early, better and more accurate diagnosis and treatment
The health group Ribera participates in a European research project, baptized as ODELIA, which seeks to facilitate the massive analysis of patient data, thanks to Artificial Intelligence (AI) to prevent breast cancer. Specifically, and as explained by the ODELIA management, this project aims to "overcome the obstacles to the collection of information on the health of patients with guarantees", to advance in an early, better and more precise diagnosis and treatment. of different pathologies, especially some types of cancer, such as breast cancer.
Ribera is a benchmark in the diagnosis and treatment of breast cancer, with a Breast Area led by Dr. Julia Camps and made up of a multidisciplinary team of almost a hundred professionals. The participation of the Ribera health group, through its foundation, in this European project allows it to be part of the team that is already designing open source software to develop the first clinically useful AI algorithm for the detection of breast cancer in MRI magnetic.
About Odelia
The ODELIA consortium brings together partners from twelve academic institutions and industrial partners from all over Europe, specifically: the European Institute for Research in Biomedical Imaging (Austria), the University Hospital of Aachen (Germany), the Vall d'Hebron Institute of Oncology ( Spain), Mitera Hospita (Greece), Radboud University Medical Center (Netherlands), University Medical Center Utrecht (Netherlands), Ribera Health Group (Spain), Fraunhofer Institute for Digital Medicine MEVIS (Germany), OSMIS (Belgium), Technische Universität Dresden (Germany), University of Zurich (Switzerland) ) and the University of Cambridge (United Kingdom). The project will be developed until December 2027 and has financing of around 8,6 million euros.
